Ensuring Critical Regulatory Alignment, Adopting Next-Generation Analytical Methods & Improving Characterization, Quality & Potency to
Safeguard the Commercial Release of Highly Efficacious
mRNA Therapeutics & Vaccines for Patients
February, 13-15, 2024 | Boston, MA
As access to faster and higher-throughput analytical methods becomes increasingly vital, it is critical that we employ superior analytical approaches for mRNA-based therapeutics and vaccines to ensure we safeguard the identity, safety, and efficacy of these promising medicines.
The 3rd mRNA Analytical Development Summit returns to Boston in February as the industry’s leading forum dedicated to sharing the latest advances in novel analytical techniques to guarantee the extensive characterization of mRNA and nanoparticle quality attributes.
Designed for Analytical Development, Quality Control, CMC, and Regulatory specialists, this must-attend meeting will unite leading biopharma and academia seeking to stay at the forefront of mRNA therapeutic and vaccine development. Join 180+ of your fellow experts and enthusiasts from across the globe to glean insights into future analytical methods to safeguard your regulatory submissions in 2024 and beyond.





Paolo Martini
CSO International Therapeutics Research Centers, Founder of Moderna Rare Diseases
Moderna
